Puma Biotechnology | PBYI - Passivo Circulante





Passivo Circulante Alterar Data
Agios Pharmaceuticals USD 58.84M 23.36M 2026-03
Alnylam Pharmaceuticals USD 1.35B 116.87M 2026-03
Amgen USD 24.96B 534M 2026-03
Biogen USD 3B 350.5M 2026-03
BioMarin Pharmaceutical USD 793.15M 34.12M 2026-03
Daiichi Sankyo JPY 778.55B 77.51B 2025-12
Esperion Therapeutics USD 300.81M 58.22M 2025-12
Exelixis USD 405.64M 31.86M 2025-12
Gilead Sciences USD 11.81B 485M 2025-12
Glaxosmithkline GBP 28.82B 144.79M 2025-12
Incyte USD 1.49B 25.52M 2026-03
MacroGenics USD 43.11M 1.36M 2025-12
Moderna USD 2.4B 408M 2026-03
Novartis USD 31.37B 4.1B 2026-03
Pfizer USD 34.35B 2.64B 2026-03
PTC Therapeutics USD 968.43M 102.18M 2025-12
Puma Biotechnology USD 82.73M 3.63M 2025-09
Regeneron Pharmaceuticals USD 5.11B 739.3M 2026-03
Roche Holding CHF 28B 421M 2025-12
Sangamo BioSciences USD 47.66M 1.9M 2025-06
Sarepta Therapeutics USD 1.1B 173.86M 2025-12
Takeda JPY 2.61T 470.53B 2025-12
TG Therapeutics USD 153.76M 3.05M 2025-12
Ultragenyx Pharmaceutical USD 384M 43.98M 2025-12
Vanda Pharmaceuticals USD 145.16M 27.29M 2025-12
Vertex Pharmaceuticals USD 3.88B 19.4M 2026-03